Education and Training
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
The purpose of this research study is to see if patients' tumor can be identified by 18F-DCFPyL PET/MRI scan. The radioactive study agent, 18FDCFPyL, combined with PET/MRI scan may be able to identify smaller tumors than the standard of care contrast-enhanced CT or MRI scan.
Stanford Investigator(s):
Intervention(s):
- drug: F18-DCFPyL
- drug: Gadolinium
- procedure: Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan
Eligibility
Inclusion Criteria:
1. Patient is older than 18-year-old
2. Biopsy proven prostate adenocarcinoma
3. Planned prostatectomy with lymph node dissection
4. Intermediate to high-risk disease (as determined by elevated Prostate-specific antigen
(PSA) [PSA>10], T-stage [T2b or greater], Gleason score [Gleason score > 6] or other
risk factors)
5. Able to provide written consent
6. Karnofsky performance status of ³50 (or Eastern Cooperative Oncology Group (ECOG)
/World Health Organization (WHO) equivalent)
Exclusion Criteria:
1. Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy including focal
ablation techniques (HiFu)
2. Androgen deprivation therapy or other neoadjuvant treatments prior to PET imaging
surgery
3. Metallic implants (contraindicated for MRI)
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Male
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pranav Hedge
650-721-4080